Bemfola, which contains the active substance follitropin alfa, is generally used to help manage symptoms related to specific reproductive hormone deficiencies and infertility treatments. It is applied across domains where additional symptomatic support is needed in the therapeutic domain of fertility support. It may be part of symptomatic management for several condition categories, including conditions characterized by periods of heightened symptoms such as anovulation, and supporting patients during phases of Assisted Reproductive Technologies (ART), as well as addressing symptoms related to systemic imbalance in men.

---

Bemfola is commonly used in situations involving certain distressing symptoms in women who are unable to ovulate naturally, or is applied in clinical settings that involve acute or unstable symptom patterns. It is used to help address symptom clusters that may become intense or disruptive, and supports the handling of distressing manifestations related to prolonged conception efforts. In relevant therapeutic contexts, this therapy contributes to easing the overall symptom load by supporting general well-being during symptomatic phases.

---

Quick Fact: Relief for Functional Strain

Bemfola contributes to improved comfort during periods of heightened symptoms.

Regulatory References

1. European Medicines Agency therapeutic overview

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adult women ( 18 years) for ovulation induction or controlled ovarian stimulation (ART).
• Adult men ( 18 years) for stimulation of spermatogenesis in hypogonadotrophic hypogonadism (with concomitant hCG).

Populations for whom use is contraindicated:

• Prior hypersensitivity to follitropin alfa or excipients.
• Presence of tumours of the hypothalamus or pituitary gland.
• Presence of sex hormone-dependent tumours (e.g., ovarian, breast, uterine, or testicular cancer).
• Primary gonadal failure (indicated by high endogenous FSH levels).
• Uncontrolled non-gonadal endocrinopathies (e.g., thyroid or adrenal dysfunction) that have not been adequately treated.
• Women with unexplained abnormal uterine bleeding, unexplained ovarian cyst or enlargement, or uterine fibroids or sexual organ malformations incompatible with pregnancy.
• Women who are pregnant.

Age and Condition-Based Restrictions

• Paediatric and Elderly Populations: Use is not established and not recommended, as safety and efficacy data are absent.
• Organ Impairment: Use is not established in patients with renal or hepatic impairment.
• Lactation: The medicine is not recommended for use in women who are breastfeeding.

Interactions with other medicines and products

Bemfola’s official interaction profile primarily focuses on its required co-administration with other hormones, rather than on adverse drug-drug interactions. Due to its nature as a recombinant therapeutic protein, regulatory documents confirm the absence of documented pharmacokinetic interactions. Official labeling explicitly states that no dedicated drug-drug interaction studies have been conducted to assess its effect on or from common metabolic pathways like CYP enzymes or drug transporters. This means that Bemfola is not formally associated with the typical metabolic drug interaction pathways found in the labels of non-protein medicines.

The documented interactions are categorized as pharmacodynamic co-use requirements or potentiating effects with other hormonal agents.

Interacting Category	Official Regulatory Statement
Mandatory Co-use	Human Chorionic Gonadotrophin (hCG) is required for co-administration in men with hypogonadotrophic hypogonadism to stimulate spermatogenesis.
Dose-Altering Co-use	The concurrent use of Gonadotropin-Releasing Hormone (GnRH) agonists or antagonists may necessitate an increased dosage of follitropin alfa to achieve the desired ovarian response.
Potentiating Effect	Co-administration with other ovulation stimulators (such as Clomiphene Citrate or other Follicle Stimulating Hormone preparations) may potentiate the overall ovarian follicular response.

The overall regulatory structure defines the product's interaction profile predominantly through therapeutic co-administration constraints necessary to achieve the desired clinical outcome.

Highly Specific Follicle-Stimulating Hormone Receptor (FSHR) Agonism

The mechanism of Follitropin alfa begins with its role as a direct agonist that exclusively targets the Follicle-Stimulating Hormone Receptor (FSHR). This receptor is located on the surface of granulosa cells in the ovary (and Sertoli cells in the testis). By binding to the FSHR, Follitropin alfa successfully mimics the action of the body’s natural FSH, acting as a sustained hormonal stimulus directly to the final target organ.

---

Intracellular Signal Transduction via cAMP Cascade

Receptor binding activates the G-protein coupled cascade, initiating a robust signaling cascade inside the target cell. This signal activates the enzyme adenylyl cyclase, resulting in an increase in the second messenger, cyclic AMP (cAMP). The cAMP pathway is essential because it instructs the cell nucleus to undergo proliferation and differentiation, while also upregulating the cellular machinery responsible for hormone synthesis, such as aromatase.

---

Modulation of Gonadal Proliferation and Endocrine Output

The molecular cascade leads to the combined physiological effects of tissue growth and enhanced endocrine output. This stimulus drives the multiplication and maturation of granulosa cells, resulting in the recruitment and physical growth of ovarian follicles. The concurrent increase in hormonal synthesis capacity results in elevated systemic secretion of Estradiol, which is the chemical marker reflecting the result of the proliferative stimulus. The overall action offers the stimulus required for the development of gamete-producing structures.

Bemfola is a solution for injection administered subcutaneously (under the skin) using a pre-filled pen. Treatment must be initiated under the supervision of a physician experienced in fertility disorders, and the first injection must be performed under direct medical supervision.

Official Administration Guidelines

Administration Scope	Clinical Guidelines
Route & Timing	Subcutaneous injection, administered daily at the same time each day.
Preparation	The solution must be clear and colourless; do not inject if it contains particles. No reconstitution is required. If refrigerated, remove 5–10 minutes before use.
Dosing (Women with Anovulation)	Typically starts at 75–150 IU FSH daily, adjusted by 37.5 or 75 IU at 7- or 14-day intervals. The maximal daily dose is usually not higher than 225 IU.
Dosing (Women undergoing ART)	Typically starts at 150–225 IU daily, commencing on Days 2 or 3 of the cycle. Dose is adjusted, usually not higher than 450 IU daily.
Dosing (Men with Hypogonadism)	150 IU three times a week, given concomitantly with Human Chorionic Gonadotrophin (hCG).
Injection Procedure	The injection site (lower abdominal area or front of the thigh) must be alternated daily. Following injection, wait 5 seconds before removing the needle.
Missed Dose	Contact the doctor or nurse immediately for advice; do not inject a double dose.

All patients must be well motivated and adequately trained prior to self-administration. The dose regimen is highly tailored to the individual patient's response, which is continuously assessed by medical monitoring, typically via ultrasound and/or oestrogen levels.

Research Evidence / Overview of Studies for Bemfola

Evidence for Controlled Ovarian Stimulation (COS) in ART

Bemfola was studied for its use in adult women undergoing fertility treatments as part of Assisted Reproductive Technology (ART), such as in vitro fertilization (IVF). The main body of research involved Randomized Controlled Trials (RCTs) that were evaluated in populations of women typically considered normal ovarian responders. These studies were designed primarily to show that the biosimilar is therapeutically similar to the reference product. Research examined several outcomes, most notably the number of eggs (oocytes) retrieved after stimulation.

However, the primary equivalence trials that underpin the authorization explored short-term outcomes. While follow-up data was observed in some studies to measure live birth rates, the follow-up durations were limited when considering the full reproductive lifetime. The long-term data are not fully established beyond the observation period of the initial research.

Evidence for Anovulation and Infertility (Extrapolated Use)

The authorization for using this medicine in women who experience conditions characterized by fluctuating or episodic manifestations like anovulation, including Polycystic Ovary Syndrome (PCOS), relies mainly on the principle of regulatory extrapolation. Research for this use relies on evidence extrapolated from primary trials and established data for the original medicine. The available research examined outcomes related to systemic or functional imbalance, monitoring hormone levels and the growth of ovarian follicles.

Crucially, data for certain groups remain insufficient, as dedicated, head-to-head RCTs comparing Bemfola specifically against other standard treatments for anovulation are still emerging. Comparative evidence is lacking for patients whose conditions involve periods of heightened symptoms or irregular cycles.

Main Uncertainties and Gaps in the Research Landscape

This medicine was studied for therapeutic similarity to the original reference product, but this approach inherently means that comparative evidence is lacking for many broader clinical questions. For instance, evidence is limited regarding how Bemfola compares to other similar medicines currently in use. The reliance on extrapolation for the anovulation and male indications means that direct evidence from dedicated trials for those specific uses is still emerging. Ultimately, evidence quality varies across studies, and the available research highlights what is known — and what is still uncertain — about how different individuals may respond over extended periods.

Common questions about Bemfola (FAQ)

Q: What is Bemfola?

A: Bemfola is a medicine that contains the active substance follitropin alfa, which is a type of recombinant human Follicle-Stimulating Hormone (FSH). FSH belongs to the group of hormones called gonadotropins, which play a key role in reproduction.

Bemfola is a biosimilar medicine, meaning it is highly similar to a reference medicine already authorized in the European Union, which is Gonal-f.

---

Q: What is the main use of Bemfola?

A: Bemfola is primarily used to treat infertility in adults. It is used to stimulate the growth and development of follicles in the ovaries, which contain eggs.

Specifically, it is used in the following ways:

• To treat women who are not ovulating and who have not responded to treatment with clomiphene citrate.
• To stimulate the development of multiple follicles in women undergoing Assisted Reproductive Technologies (ART) like in vitro fertilization (IVF).
• In combination with a luteinizing hormone (LH) preparation, to stimulate follicular development in women with severe LH and FSH deficiency.

---

Q: How is Bemfola given?

A: Bemfola is administered as an injection under the skin (subcutaneously). The injection is typically given once a day.

It is supplied in a pre-filled pen injector that delivers a single, adjustable dose. The first injection of Bemfola should be given under the direct supervision of a healthcare professional. Subsequent self-administration at home should only be done by patients who have been properly trained and have access to expert advice.

---

Q: What are common side effects of Bemfola?

A: Like all medicines, Bemfola can cause side effects, though not everyone gets them.

Very common side effects (may affect more than 1 in 10 people) include:

• Headache
• Reactions at the injection site (such as pain, redness, or swelling)

Common side effects (may affect up to 1 in 10 people) include:

• Mild to moderate Ovarian Hyperstimulation Syndrome (OHSS)
• Abdominal pain or discomfort
• Nausea and vomiting
• Diarrhea
• Cysts on the ovaries

Severe OHSS is a less common but serious side effect that requires immediate medical attention. Your doctor will monitor you closely during treatment to help prevent this.

How to Store and Dispose of Bemfola

Bemfola (follitropin alfa) solution for injection requires specific storage and handling to maintain its stability, as stipulated in regulatory documents.

---

Official Storage Conditions

The unopened pre-filled pen must be stored in a refrigerator at a temperature between 2 C and 8 C. It is a mandatory requirement that the medicine must not be frozen. The pen must be kept in the original package to protect it from light. The product can be stored outside the refrigerator, at or below 25 C, for a maximum period of 3 months before opening, but must be discarded if unused after this time. This medicine must also be kept out of the sight and reach of children.

---

Disposal Instructions

As a single-use device, the used pen and needle must be discarded immediately after the injection is completed. Any unused medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.